Tucotuzumab celmoleukin
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | EpCAM |
| Identifiers | |
| CAS Number | 339986-90-2  |
| ATC code | none |
| KEGG | D09027 |
| Chemical data | |
| Formula | C7812H12124N2044O2408S60 |
| Molecular mass | 175.1 kDa |
| (verify) | |
Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).[1][2][3]
This drug was developed by EMD Pharmaceuticals.
References
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin, American Medical Association.
- ↑ ClinicalTrials.gov
- ↑ National Cancer Institute: Definition of tucotuzumab celmoleukin
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies for tumors
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
